Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Long-Term Investments (2021 - 2023)

Bioregenx has reported Long-Term Investments over the past 3 years, most recently at $100.0 for Q4 2023.

  • For Q4 2023, Long-Term Investments fell 99.52% year-over-year to $100.0; the TTM value through Dec 2023 reached $100.0, down 99.52%, while the annual FY2023 figure was $100.0, 99.52% down from the prior year.
  • Long-Term Investments for Q4 2023 was $100.0 at Bioregenx, down from $200.0 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $60000.0 in Q4 2021 and troughed at $100.0 in Q4 2023.
  • A 3-year average of $29050.0 and a median of $31500.0 in 2022 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: crashed 65.0% in 2022 and later crashed 99.52% in 2023.
  • Year by year, Long-Term Investments stood at $60000.0 in 2021, then crashed by 65.0% to $21000.0 in 2022, then crashed by 99.52% to $100.0 in 2023.
  • Business Quant data shows Long-Term Investments for BRGX at $100.0 in Q4 2023, $200.0 in Q3 2023, and $51000.0 in Q2 2023.